Work

A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC)

Year: 2008

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2008.26.15_suppl.3522

Authors: R. Salgia, S. Sherman, D. S. Hong, C. S. Ng, J. Frye, L. Janisch, M. J. Ratain, R. Kurzrock

Language: English

Topic: Thyroid Cancer Diagnosis and Treatment

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2246590687

Cites:

Cited by: 78

Related to: 10